FindTrial
Sign In

Tofacitinib ointment in patchy hair loss.

Clinical efficacy of topical tofacitinib in alopecia areata - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/02/062305
Enrollment
30
Registered
2024-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L63- Alopecia areata

Interventions

Intervention1: Tofacitinib: Pharmacological category: Janus kinase inhibitor Mode: 2% Tofacitinib ointment, topical application, twice daily. Duration: 12 weeks Control Intervention1: NIL: NIL

Sponsors

Government Medical College and Hospital, Sector 32,Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All consecutive patients (age 6 year or above) having clinical diagnosis of alopecia areata. 2. Patients with disease of limited area not requiring systemic treatment.

Exclusion criteria

Exclusion criteria: 1. Immunocompromised individuals including HIV-AIDS. 2. Patients having any significant systemic illness. 3. History of taking any topical or systemic treatment for AA in past six weeks.

Design outcomes

Primary

MeasureTime frame
percentage improvement in the SALT score or area of the lesionTimepoint: 0,3,6,9,12 weeks—

Secondary

MeasureTime frame
Photographic assessment, alopecia areata investigator global assessment scale (AA-IGA)Timepoint: 0,3,6,9,12 weeks—

Countries

India

Contacts

Public ContactDr Mala Bhalla

Government Medical College and Hospital, Sector 32,Chandigarh

malabhalla@yahoo.co.in9646121545

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026